Risk factors for slowly resolving pneumonia in the intensive care unit

J Microbiol Immunol Infect. 2016 Oct;49(5):654-662. doi: 10.1016/j.jmii.2014.11.005. Epub 2014 Nov 22.

Abstract

Background: Slowly resolving pneumonia (SRP) poses early challenges for identification and medical expense for clinicians in intensive care units (ICUs); to date, the literature has been very limited in this regard.

Methods: This was a retrospective and cohort-based study in the ICU of a university-affiliated hospital in Shanghai. Medical records of pneumonia patients in the ICU between April 2008 and February 2011were reviewed retrospectively to evaluate the risk factors for SRP.

Results: In all, 106 pneumonia patients in the ICU were identified as immune-competent with a diagnosis of bacterial pneumonia. There were 62 (58.49%) patients who showed SRP and their radiographic infiltrations were completely resolved between 5 weeks and 8 weeks. Multivariate logistic regression analysis demonstrated that initial treatment with an inappropriate antibiotic, multilobar infiltration, and a high CURB-65 score were independent risk factors for SRP, with odds ratio (OR) values of 8.338 [95% confidence interval (CI) 2.117-32.848], 11.184 (95% CI 2.526-49.514), and 2.329 (95% CI 1.172-4.626), respectively. The length of the ICU stay in the SRP group was twice as long as that of the normally resolving pneumonia (NRP) group (62.27 ± 73.73 vs. 32.25 ± 23, p = 0.002). The 28-day and 60-day mortality rates in the SRP group were 17.74% and 25.81%, respectively. In addition, the 60-day mortality rate was significantly higher in the SRP group than the NRP group (25.81% vs. 6.82%, respectively; p = 0.012). Moreover, SRP was an independent risk factor for 60-day mortality (OR 5.687, 95% CI 1.334-24.240).

Conclusion: Treatment with an inappropriate antibiotic, multilobar infiltration, and a high CURB-65 score were independent risk factors for SRP.

Keywords: antibiotic therapy; critically ill; pneumonia; radiographic infiltrations; resolution; risk factors.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Cohort Studies
  • Critical Illness / economics
  • Critical Illness / therapy*
  • Female
  • Hospital Mortality*
  • Humans
  • Intensive Care Units / economics
  • Intensive Care Units / statistics & numerical data*
  • Length of Stay
  • Male
  • Medication Errors / statistics & numerical data*
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / economics
  • Retrospective Studies
  • Risk Factors

Substances

  • Anti-Bacterial Agents